732 reports of this reaction
2.5% of all BRIMONIDINE TARTRATE reports
#4 most reported adverse reaction
EYE IRRITATION is the #4 most commonly reported adverse reaction for BRIMONIDINE TARTRATE, manufactured by Sandoz Inc. There are 732 FDA adverse event reports linking BRIMONIDINE TARTRATE to EYE IRRITATION. This represents approximately 2.5% of all 28,834 adverse event reports for this drug.
Patients taking BRIMONIDINE TARTRATE who experience eye irritation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE IRRITATION is a less commonly reported adverse event for BRIMONIDINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to eye irritation, the following adverse reactions have been reported for BRIMONIDINE TARTRATE:
The following drugs have also been linked to eye irritation in FDA adverse event reports:
EYE IRRITATION has been reported as an adverse event in 732 FDA reports for BRIMONIDINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE IRRITATION accounts for approximately 2.5% of all adverse event reports for BRIMONIDINE TARTRATE, making it a notable side effect.
If you experience eye irritation while taking BRIMONIDINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.